UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The Landscape of Targeted Therapies in TNBC

Cancers, 2020-04, Vol.12 (4), p.916

2020

Volltextzugriff (PDF)

Review: Oncolytic virotherapy, updates and future directions

Oncotarget, 2017-11, Vol.8 (60), p.102617-102639

2017

Volltextzugriff (PDF)

Immunotherapy in pancreatic adenocarcinoma-overcoming barriers to response

Journal of gastrointestinal oncology, 2018-02, Vol.9 (1), p.143-159

2018

Volltextzugriff (PDF)

Targeting Epidermal Growth Factor Receptor in Triple Negative Breast Cancer: New Discoveries and Practical Insights for Drug Development

Cancer treatment reviews, 2017-02, Vol.53, p.111-119

2017

Volltextzugriff (PDF)

Modulation of autophagy: a Phase II study of vorinostat plus hydroxychloroquine versus regorafenib in chemotherapy-refractory metastatic colorectal cancer (mCRC)

British journal of cancer, 2022-10, Vol.127 (6), p.1153-1161

2022

Volltextzugriff (PDF)

Single-cell analysis of circulating tumor cells identifies cumulative expression patterns of EMT-related genes in metastatic prostate cancer

The Prostate, 2013-06, Vol.73 (8), p.813-826

2013

Volltextzugriff (PDF)

Phase II study of modulation of sorafenib (SOR)-induced autophagy using hydroxychloroquine (HCQ) in advanced hepatocellular cancer (HCC): Planned interim efficacy and safety analysis

Journal of clinical oncology, 2021-01, Vol.39 (3_suppl), p.305-305

2021

Volltextzugriff (PDF)

Short-Term Risk of Performing Concurrent Procedures with Hepatic Artery Infusion Pump Placement

Annals of surgical oncology, 2020-12, Vol.27 (13), p.5098-5106

2020

Volltextzugriff (PDF)

Autophagy inhibition enhances vorinostat‐induced apoptosis via ubiquitinated protein accumulation

Journal of cellular and molecular medicine, 2010-10, Vol.14 (10), p.2448-2459

2010

Volltextzugriff (PDF)

Estrogen and estrogen receptor alpha promotes malignancy and osteoblastic tumorigenesis in prostate cancer

Oncotarget, 2015-12, Vol.6 (42), p.44388-44402

2015

Volltextzugriff (PDF)

Systematic review and meta-analysis of selected toxicities of approved ALK inhibitors in metastatic non-small cell lung cancer

Oncotarget, 2018-04, Vol.9 (31), p.22137-22146

2018

Volltextzugriff (PDF)

618 Phase 1 clinical trial evaluating the safety, biologic and anti-tumor activity of the novel STING agonist IMSA101 administered both as monotherapy and in combination with PD-(L)1 checkpoint inhibitors

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A704-A704

2023

Volltextzugriff (PDF)

Commentary: GSK-3 Inhibition as a Therapeutic Approach Against SARs CoV2: Dual Benefit of Inhibiting Viral Replication While Potentiating the Immune Response

Frontiers in immunology, 2020-10, Vol.11, p.595289-595289

2020

Volltextzugriff (PDF)

Vorinostat Enhances the Activity of Temsirolimus in Renal Cell Carcinoma Through Suppression of Survivin Levels

Clinical cancer research, 2010-01, Vol.16 (1), p.141-153

2010

Volltextzugriff (PDF)

First-in-human phase I dose escalation trial of the first-in-class tumor microenvironment modulator VT1021 in advanced solid tumors

Communications medicine, 2024-01, Vol.4 (1), p.10-10, Article 10

2024

Volltextzugriff (PDF)

The Pim kinases: new targets for drug development

Current drug targets, 2011-12, Vol.12 (14), p.2059-2066

2011

Volltextzugriff (PDF)

Phase 1 dose expansion and biomarker study assessing first-in-class tumor microenvironment modulator VT1021 in patients with advanced solid tumors

Communications medicine, 2024-05, Vol.4 (1), p.95-95, Article 95

2024

Volltextzugriff (PDF)

651 A phase 1, multicenter, open-label, dose-escalation, safety, pharmacodynamic, pharmacokinetic study of Q702 with a cohort expansion at the RP2D in patients with advanced solid tumors

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A742-A742

2023

Volltextzugriff (PDF)

Emerging targeted therapies and strategies to overcome resistance in biliary tract cancers

Critical reviews in oncology/hematology, 2024-07, Vol.199, p.104388, Article 104388

2024

Volltextzugriff (PDF)

Targeting aurora kinases in cancer treatment

Current drug targets, 2011-12, Vol.12 (14), p.2067-2078

2011

Volltextzugriff (PDF)

369 Clinical update of VT1021, a first-in-class CD36 and CD47 targeting immunomodulating agent, in subjects with pancreatic cancer and other solid tumors stratified by novel biomarkers

Journal for immunotherapy of cancer, 2021-11, Vol.9 (Suppl 2), p.A397-A397

2021

Volltextzugriff (PDF)

525 Preliminary safety, PK/PD and efficacy results from a first-in-human phase I/IIa clinical trial of BNT411, a systemic Toll-like receptor 7 agonist in patients with solid tumors

Journal for immunotherapy of cancer, 2021-11, Vol.9 (Suppl 2), p.A555-A555

2021

Volltextzugriff (PDF)

Immunotherapy in colorectal cancer: for the select few or all?

Journal of gastrointestinal oncology, 2018-02, Vol.9 (1), p.170-179

2018

Volltextzugriff (PDF)

The coming of age: immunotherapy in gastrointestinal malignancies

Journal of gastrointestinal oncology, 2018-02, Vol.9 (1), p.140-142

Mahalingam, Devalingam

2018

Volltextzugriff (PDF)

374 A first-in-human Phase 1/2 open label trial evaluating the safety, pharmacology, and preliminary efficacy of VT1021 in subjects with advanced solid tumors

Journal for immunotherapy of cancer, 2020-11, Vol.8 (Suppl 3), p.A228-A228

2020

Volltextzugriff (PDF)

1 – 25 von 211

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(192)
Mit Volltextzugriff
(195)

Publikationsform

Sprache

Englisch
(211)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Journal Of Clinical Oncology
(59)
Cancer Research
(19)
Clinical Cancer Research
(11)
Molecular Cancer Therapeutics
(9)
Oncotarget
(9)
Blood
(7)
Cancers
(7)
Journal Of Gastrointestinal Oncology
(7)
Journal For Immunotherapy Of Cancer
(6)
Targeted Oncology
(6)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The Landscape of Targeted Therapies in TNBC

Review: Oncolytic virotherapy, updates and future directions

Immunotherapy in pancreatic adenocarcinoma-overcoming barriers to response

Targeting Epidermal Growth Factor Receptor in Triple Negative Breast Cancer: New Discoveries and Practical Insights for Drug Development

Modulation of autophagy: a Phase II study of vorinostat plus hydroxychloroquine versus regorafenib in chemotherapy-refractory metastatic colorectal cancer (mCRC)

Single-cell analysis of circulating tumor cells identifies cumulative expression patterns of EMT-related genes in metastatic prostate cancer

Phase II study of modulation of sorafenib (SOR)-induced autophagy using hydroxychloroquine (HCQ) in advanced hepatocellular cancer (HCC): Planned interim efficacy and safety analysis

Short-Term Risk of Performing Concurrent Procedures with Hepatic Artery Infusion Pump Placement

Autophagy inhibition enhances vorinostat‐induced apoptosis via ubiquitinated protein accumulation

Estrogen and estrogen receptor alpha promotes malignancy and osteoblastic tumorigenesis in prostate cancer

Systematic review and meta-analysis of selected toxicities of approved ALK inhibitors in metastatic non-small cell lung cancer

618 Phase 1 clinical trial evaluating the safety, biologic and anti-tumor activity of the novel STING agonist IMSA101 administered both as monotherapy and in combination with PD-(L)1 checkpoint inhibitors

Commentary: GSK-3 Inhibition as a Therapeutic Approach Against SARs CoV2: Dual Benefit of Inhibiting Viral Replication While Potentiating the Immune Response

Vorinostat Enhances the Activity of Temsirolimus in Renal Cell Carcinoma Through Suppression of Survivin Levels

First-in-human phase I dose escalation trial of the first-in-class tumor microenvironment modulator VT1021 in advanced solid tumors

The Pim kinases: new targets for drug development

Phase 1 dose expansion and biomarker study assessing first-in-class tumor microenvironment modulator VT1021 in patients with advanced solid tumors

651 A phase 1, multicenter, open-label, dose-escalation, safety, pharmacodynamic, pharmacokinetic study of Q702 with a cohort expansion at the RP2D in patients with advanced solid tumors

Emerging targeted therapies and strategies to overcome resistance in biliary tract cancers

Targeting aurora kinases in cancer treatment

369 Clinical update of VT1021, a first-in-class CD36 and CD47 targeting immunomodulating agent, in subjects with pancreatic cancer and other solid tumors stratified by novel biomarkers

525 Preliminary safety, PK/PD and efficacy results from a first-in-human phase I/IIa clinical trial of BNT411, a systemic Toll-like receptor 7 agonist in patients with solid tumors

Immunotherapy in colorectal cancer: for the select few or all?

The coming of age: immunotherapy in gastrointestinal malignancies

374 A first-in-human Phase 1/2 open label trial evaluating the safety, pharmacology, and preliminary efficacy of VT1021 in subjects with advanced solid tumors

Suchergebnisse filtern